Gabapentin Market Report 2026

The gabapentin market size has grown strongly in recent years. It will grow from $3.01 billion in 2025 to $3.26 billion in 2026 at a compound annual growth rate (CAGR) of 8.4%. The growth in the historic period can be attributed to epilepsy treatment adoption, neuropathic pain prevalence, generic drug availability, physician prescribing patterns, chronic disease burden.

The gabapentin market size is expected to see strong growth in the next few years. It will grow to $4.45 billion in 2030 at a compound annual growth rate (CAGR) of 8.1%. The growth in the forecast period can be attributed to aging population, diabetic neuropathy growth, generic penetration, outpatient pain management, telemedicine prescriptions. Major trends in the forecast period include rising use in neuropathic pain management, increased demand for generic formulations, expansion of chronic pain treatment programs, growth of oral solid dosage forms, increased prescriptions for neurological disorders.

The increasing prevalence of epilepsy is expected to drive the growth of the gabapentin market in the coming years. Epilepsy is a neurological disorder characterized by recurrent seizures caused by irregular electrical activity in the brain. The rising number of epilepsy cases is primarily driven by the growing elderly population, as aging increases susceptibility to neurological conditions that trigger seizures. Gabapentin manages epilepsy by stabilizing abnormal nerve activity in the brain and reducing seizure-inducing signals. It targets calcium channels to help prevent seizure occurrence. For instance, in February 2024, according to the World Health Organization (WHO), a Switzerland-based intergovernmental organization, approximately 50 million people globally have epilepsy, with nearly 80% residing in low- and middle-income countries. Up to 70% of these patients could live seizure-free with proper diagnosis and treatment. Each year, an estimated 5 million people are newly diagnosed with epilepsy worldwide; incidence rates are around 49 per 100,000 in high-income countries and can reach 139 per 100,000 in low- and middle-income countries. Therefore, the increasing prevalence of epilepsy is driving the growth of the gabapentin market.

Major companies operating in the gabapentin market are focusing on developing advanced formulations, such as bioequivalent tablets, to enhance therapeutic efficacy and expand treatment options for neurological disorders. Bioequivalent tablets are generic medications that deliver the same dose of the active ingredient into the bloodstream at the same rate and extent as branded versions, ensuring comparable safety and effectiveness. For instance, in March 2024, Strides Pharma Science Limited, an India-based pharmaceutical company, launched Gabapentin Tablets USP in 600 mg and 800 mg strengths, receiving approval from the United States Food & Drug Administration (USFDA) to expand its neurology portfolio in the US. These tablets feature enhanced bioavailability, precise dosing, and patient-friendly administration, allowing for consistent therapeutic outcomes, improved symptom control, and greater convenience for long-term therapy. Gabapentin Tablets USP, 600 mg, provide effective management of neurological conditions such as neuropathic pain and partial seizures through reliable dosing and proven clinical efficacy.

In September 2023, Adalvo, a Malta-based pharmaceutical company, collaborated with Lotus Pharmaceutical to enhance access to innovative neurological care. The partnership aims to launch Gabapentin ER in South Korea, offering a convenient once-daily treatment for postherpetic neuralgia, addressing unmet needs, and expanding market presence in neurology. Lotus Pharmaceutical is a Taiwan-based manufacturer specializing in gabapentin extended-release tablets.

Major companies operating in the gabapentin market are Pfizer Inc., Teva Pharmaceutical Industries Ltd., Mylan Inc., Apotex Inc., Sun Pharmaceutical Industries Ltd., Aurobindo Pharma Limited, Cipla Limited, Lupin Limited, Zydus Lifesciences Limited, Glenmark Pharmaceuticals Limited, Torrent Pharmaceuticals Ltd., Ipca Laboratories Private Limited, Granules India Limited, Medley Pharmaceuticals Limited, Wockhardt Limited, Epic Pharma LLC, Healing Pharma India Pvt. Ltd., Rochem International Inc., Accord Healthcare Limited, Strides Pharma Science Limited, Ascend Laboratories LLC.

North America was the largest region in the gabapentin market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the gabapentin market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the gabapentin market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have influenced the gabapentin market by raising the cost of active pharmaceutical ingredients, capsule shells, and packaging materials. Generic and extended-release formulations are most affected, particularly in Asia-Pacific and North America where large volumes of gabapentin APIs are imported. Retail and hospital pharmacies face cost increases. Positively, tariffs are promoting domestic API manufacturing and generic drug production.

The gabapentin market research report is one of a series of new reports that provides gabapentin market statistics, including gabapentin industry global market size, regional shares, competitors with a gabapentin market share, detailed gabapentin market segments, market trends and opportunities, and any further data you may need to thrive in the gabapentin industry. This gabapentin market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Gabapentin is a prescription medication primarily used to manage nerve pain, epilepsy, and restless legs syndrome. It works by targeting nerve signals and brain chemicals to control seizures and relieve nerve pain, including pain caused by shingles and diabetic neuropathy. Gabapentin helps stabilize brain activity and reduce abnormal nerve excitability.

The main types of gabapentin are generic and branded. Generic versions contain the same active ingredients and dosages as branded drugs, offering a more affordable but equally effective alternative. Gabapentin is available in various dosage forms, including tablets, capsules, and oral solutions, and is distributed through hospital pharmacies, retail pharmacies, online pharmacies, and other channels. Its applications include epilepsy, neuropathic pain, restless legs syndrome, and other conditions.

The gabapentin market consists of sales of gabapentin immediate-release, gabapentin extended-release, and oral solution. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.